Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

Enveric Biosciences ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, ...

“It is extremely encouraging to see the progress being made by Neurocrine across this exciting portfolio of muscarinic agonists and its team’s clear commitment to advancing these novel ...

“It is extremely encouraging to see the progress being made by Neurocrine across this exciting portfolio of muscarinic agonists and its team’s clear commitment to advancing these novel molecules ...

Researchers at Durham University have successfully demonstrated long-lasting quantum entanglement between molecules, opening new doors for future advancements in quantum computing, sensing ...

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Neurocrine (NBIX – Research Report) on January 31 and set a price target of $190.00. The company’s shares closed last Friday at ...